Trending Stock News

Hamel Associates Upped Its Consolidated Edison (ED) Position; Spark Therapeutics, Inc. (ONCE) Had 15 Analysts Last Week

Spark Therapeutics, Inc. (NASDAQ:ONCE) Logo

Hamel Associates Inc increased Consolidated Edison Inc (ED) stake by 16.36% reported in 2018Q1 SEC filing. Hamel Associates Inc acquired 6,423 shares as Consolidated Edison Inc (ED)’s stock declined 1.36%. The Hamel Associates Inc holds 45,679 shares with $3.56 million value, up from 39,256 last quarter. Consolidated Edison Inc now has $23.45 billion valuation. The stock increased 0.56% or $0.42 during the last trading session, reaching $75.45. About 1.97 million shares traded or 8.90% up from the average. Consolidated Edison, Inc. (NYSE:ED) has declined 7.47% since June 21, 2017 and is downtrending. It has underperformed by 20.04% the S&P500. Some Historical ED News: 12/04/2018 – EPRI Announces Changes to Board of Directors; 24/04/2018 – CONSOLIDATED EDISON INC – CON EDISON IS NOT ASSOCIATED WITH TRC CAPITAL, ITS MINI-TENDER OFFER OR MINI-TENDER OFFER DOCUMENTATION; 03/05/2018 – CONSOLIDATED EDISON INC – QTRLY TOTAL OPERATING REVENUES $3,364 MLN VS $3,228 MLN; 03/05/2018 – CONSOLIDATED EDISON INC ED.N FY2018 SHR VIEW $4.26 — THOMSON REUTERS l/B/E/S; 03/05/2018 – Consolidated Edison 1Q Net $428M; 03/05/2018 – Consolidated Edison 1Q Rev $3.36B; 24/04/2018 – Consolidated Edison, Inc. Recommends Shareholder Rejection of Mini-Tender Offer by TRC Capital Corporation; 23/04/2018 – CONSOLIDATED EDISON INC ED.N : UBS RAISES TARGET PRICE TO $79 FROM $77; 03/05/2018 – CONSOLIDATED EDISON INC ED.N REAFFIRMS FY 2018 ADJUSTED SHR VIEW $4.15 TO $4.35; 03/05/2018 – CONSOLIDATED EDISON INC – FOR 2018, CONFIRMS ITS PREVIOUS FORECAST OF ADJUSTED EARNINGS IN THE RANGE OF $4.15 TO $4.35 PER SHARE

Among 26 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 2 Sell and 9 Hold. Therefore 58% are positive. Spark Therapeutics had 79 analyst reports since August 21, 2015 according to SRatingsIntel. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Outperform” rating given on Wednesday, February 21 by BMO Capital Markets. The company was maintained on Tuesday, May 8 by Cantor Fitzgerald. On Thursday, June 23 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Neutral” rating given on Tuesday, May 1 by JP Morgan. The stock has “Buy” rating by BMO Capital Markets on Wednesday, January 24. As per Friday, October 13, the company rating was maintained by Barclays Capital. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Wednesday, February 21 by Stifel Nicolaus. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, June 3. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Neutral” rating by Chardan Capital Markets on Monday, April 23. See Spark Therapeutics, Inc. (NASDAQ:ONCE) latest ratings:

22/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $103.0000 Maintain
09/05/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $64 New Target: $78 Maintain
09/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $64 New Target: $76 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $103.0000 Maintain
07/05/2018 Broker: Leerink Swann Rating: Hold New Target: $74.0000 Maintain
01/05/2018 Broker: Mizuho Rating: Buy New Target: $91.0000 Maintain
01/05/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $60 New Target: $63 Maintain
01/05/2018 Broker: Citigroup Rating: Neutral New Target: $85 Initiates Coverage On
30/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $103.0000 Maintain
23/04/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Neutral Downgrade

More recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Second Sight Medical Products, ICF International, Morningstar, Spark …” on June 21, 2018. Also 247Wallst.com published the news titled: “Top Analyst Upgrades and Downgrades: Citigroup, Oracle, PTC Therapeutics, Starbucks, Tableau Software, Williams …” on June 20, 2018. Seekingalpha.com‘s news article titled: “Weekly Wrap For June 8, 2018” with publication date: June 10, 2018 was also an interesting one.

The stock decreased 2.32% or $2.1 during the last trading session, reaching $88.49. About 553,785 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 41.78% since June 21, 2017 and is uptrending. It has outperformed by 29.21% the S&P500. Some Historical ONCE News: 11/05/2018 – Spark Therapeutics Forms Golden Cross: Technicals; 08/05/2018 – Spark Therapeutics 1Q Loss $46.4M; 09/03/2018 – CHILDREN’S HOSPITAL OF PHILADELPHIA FOUNDATION – TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER; 15/05/2018 – Partner Management Buys New 1.7% Position in Spark Therapeutics; 09/04/2018 – Spark Therapeutics Closes Above 200-Day Average: Technicals; 08/05/2018 – SPARK THERAPEUTICS INC ONCE.O : RBC RAISES TARGET PRICE TO $75 FROM $65; 09/03/2018 – CHILDREN’S HOSPITAL OF PHILADELPHIA FOUNDATION – TO CONSIDER VIEW OF ISS, AMONG OTHERS REGARDING ELECTION OF SPARK THERAPEUTICS’ BOARD AT 2018 MEETING; 08/05/2018 – SPARK THERAPEUTICS 1Q LOSS/SHR $1.25, EST. LOSS/SHR 32C; 30/04/2018 – ONCE TO SELL RARE PEDIATRIC DISEASE PRV FOR $110M; 07/05/2018 – SPARK THERAPEUTICS INC ONCE.O : LEERINK RAISES TARGET PRICE TO $74 FROM $55

Investors sentiment decreased to 1.19 in Q1 2018. Its down 0.24, from 1.43 in 2017Q4. It worsened, as 21 investors sold Spark Therapeutics, Inc. shares while 42 reduced holdings. 33 funds opened positions while 42 raised stakes. 36.74 million shares or 2.75% more from 35.76 million shares in 2017Q4 were reported. Amer International Group accumulated 17,667 shares. Parametric Portfolio Assocs Ltd owns 7,906 shares for 0% of their portfolio. Manufacturers Life The, Ontario – Canada-based fund reported 20,884 shares. 2.64 million are owned by Vanguard. Armistice Capital Limited Liability Company stated it has 0.92% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Nj State Employees Deferred Compensation Plan reported 4,000 shares. Connecticut-based Great Point Ltd Liability Corporation has invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Great West Life Assurance Co Can reported 3,939 shares. Sector Gamma As stated it has 0.56% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Bancorporation Of Ny Mellon has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Smith Asset Mngmt Group Lp has 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 2,830 shares. France-based Exane Derivatives has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Pnc Fincl Grp Inc has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 2,100 shares. C Ww Wide Grp Inc Holdings A S has invested 0.04% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Cwm has invested 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE).

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $3.31 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Investors sentiment decreased to 0.89 in 2018 Q1. Its down 0.17, from 1.06 in 2017Q4. It dived, as 51 investors sold ED shares while 247 reduced holdings. 74 funds opened positions while 192 raised stakes. 173.02 million shares or 2.20% more from 169.29 million shares in 2017Q4 were reported. Thrivent For Lutherans, Minnesota-based fund reported 12,940 shares. 2,000 were accumulated by Kelly Lawrence W Associate Inc Ca. Morgan Stanley stated it has 2.43M shares. Colonial Tru Advsr invested 0.05% of its portfolio in Consolidated Edison, Inc. (NYSE:ED). Seabridge Invest Advsrs Ltd has invested 0.01% in Consolidated Edison, Inc. (NYSE:ED). State Of New Jersey Common Pension Fund D accumulated 0.02% or 58,000 shares. Horizon Investments Lc holds 0.06% of its portfolio in Consolidated Edison, Inc. (NYSE:ED) for 18,115 shares. Janney Montgomery Scott Ltd stated it has 0.05% in Consolidated Edison, Inc. (NYSE:ED). Guggenheim Capital Limited Liability invested in 634,760 shares or 0.12% of the stock. Clearbridge Invs Lc has 0% invested in Consolidated Edison, Inc. (NYSE:ED) for 23,736 shares. Carroll reported 0.03% in Consolidated Edison, Inc. (NYSE:ED). Tiedemann Advsrs Limited has 8,900 shares. Stifel Fincl holds 0.02% or 78,863 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt has invested 0.03% in Consolidated Edison, Inc. (NYSE:ED). First Quadrant Ltd Partnership Ca has invested 0.01% of its portfolio in Consolidated Edison, Inc. (NYSE:ED).

Since December 31, 2017, it had 53 buys, and 1 sale for $150,984 activity. $2,344 worth of Consolidated Edison, Inc. (NYSE:ED) shares were bought by Cawley Timothy. 51 shares were bought by McAvoy John, worth $4,442. Shares for $687 were bought by OATES JOSEPH P. $87 worth of Consolidated Edison, Inc. (NYSE:ED) was bought by Ivey Craig S. Nadkarni Gurudatta D bought $6,942 worth of Consolidated Edison, Inc. (NYSE:ED) on Saturday, March 31. $3,745 worth of Consolidated Edison, Inc. (NYSE:ED) was bought by Sanchez Robert. Shares for $2,261 were bought by Moore Elizabeth D on Monday, April 30.

Consolidated Edison, Inc. (NYSE:ED) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *